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SUMMARY
Objective: To identify whether cutoff for sensitivity advertised by three pregnancy tests 
in urine are compatible to those reported by the manufacturer and to describe their 
diagnostic performance. Methods: The urine of a male volunteer was used to dilute re-
combinant β-hCG at defined concentrations of 0, 6.25, 12.5, 25, 50, and 100 mIU/mL. 
The tubes containing each of the concentrations were coded and blindly assessed for 
positivity in three different lots of hCG tests: Strip Test Plus®, BioEasy®, and Visitect Preg-
nancy®. The sample size was calculated for an alpha error of 5%, with a power of 99%. 
Results: All three brands, in their three lots analyzed, had 100% of sensitivity for de-
tecting β-hCG, with 100% negative predictive value, using only negative controls and 
samples with concentrations equal or higher than the test cutoff (n = 180/brand). The 
accuracy of the tests was 83% (BioEasy®), 84%(Visitect®) and 91% (Strip Test Plus®). Strip 
Test Plus® had the best positive likelihood ratio (52.5), while Visitect® had the best nega-
tive likelihood ratio (zero). Conclusion: The three brands have adequate sensitivity for 
the advertised cutoffs. The Strip Test Plus® test had the best performance to identify uri-
nary concentrations of β-hCG ≥ 12.5 mIU/mL, and consequently, to confirm pregnancy, 
while Visitect® had the best performance to exclude β-hCG in urine (negative post-test 
probability: zero). 
Keywords: Pregnancy tests; urine; reagent kits, in vitro diagnosis; chorionic gonadotropin.
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INTRODUCTION
Urine pregnancy tests have been widely used and accepted 
as the first step in detecting early pregnancy in gynecologi-
cal emergencies1, as in addition to being rapid2, the current 
qualitative pregnancy tests in serum or urine have similar 
sensitivity3. Since their introduction in the market in 1975, 
the number of available brands has significantly increased, 
with the production of monoclonal antibodies against the 
β subunit of hCG and the use of enzyme immunoassays 
that solved the problems of using radioimmunoassay. Ini-
tially, these tests needed 2 hours to show the result.  
In the 1980s, the immunochromatic tests to detect 
hCG in urine appeared, and in the 1990s, the generation of 
the “dipstick” test emerged4. Currently, manufacturers 
of these products advertise sensitivity of 25 mIU/mL, and 
accuracy between 97 and 99%3. This sensitivity to detect 
urinary hCG is not affected by the dilution of urine5, un-
less tests with sensitivity > 200 mIU/mL are used6. Howev-
er, international studies have shown that these parameters 
advertised by the manufacturers are not reproduced by 
independent researchers7,8. Cervinski et al.9 demonstrated 
that some types of pregnancy tests in urine have better 
analytical sensitivity when compared to others. Tomlin-
son et al.10 compared the accuracy of six pregnancy tests 
and verified that the method that used a digital system to 
give the result had significantly better accuracy compared 
to the other methods.   
In Brazil, there are more than 100 types of tests to detect 
the presence of pregnancy in urine; some manufacturers 
give unclear information about product accuracy, such as 
for instance, “this test has 99.4% of agreement with results 
obtained with the use of other immunological pregnancy 
tests previously qualified by current clinical practice”11. 
In Brazil, the In-Vitro Diagnostic Product Team (GE-
VIT / GGTPS) of the National Health Surveillance Agency 
(ANVISA) says “the methods used for product qualifica-
tion have not yet been determined or listed by ANVISA, 
but each manufacturer determines, among the methods 
recognized in international procedures, those that best suit 
their needs”. Given that the data submitted for the prod-
ucts come from the manufacturers themselves, it would be 
important, compared to what is done in the international 
literature, to verify whether the advertised accuracy can be 
reproduced by independent investigators.  
Moreover, a search for law cases related to pregnan-
cy tests at JusBrasil site (www.jusbrasil.com.br) reveals 
that there are 1,639 civil cases related to false-positive or 
false-negative results (search performed on 04/12/2011, 
keywords: pregnancy test). Similar cases have been de-
scribed in the literature12,13. The importance of this study 
is the precise information on the accuracy of the product 
and on their threshold sensitivity values  for the detection 
of hCG, so that doctors can understand test results and 
medical experts can have foundations in legal proceedings. 
The objectives of this research are to identify whether the 
cutoff sensitivity of three products used for the diagnosis 
of urinary hCG are consistent with those announced by 
the manufacturers, as well as to describe their diagnostic 
performance (sensitivity, specificity, positive and negative 
predictive values, accuracy, positive and negative likeli-
hood ratios), with known concentrations of recombinant 
β-hCG diluted in urine as reference standards. 
METHODS
ANALYZED PRODUCTS 
Three brands of immunochromatographic pregnancy tests 
in urine available in the Brazilian market were obtained: 
hCG Strip Test Plus® (InLab Diagnostica, SP, Brazil), 
β-hCG S&U One Step BioEasy® (Acon Biotech Hangzhou, 
China) and Visitect Pregnancy® (Omega Diagnostics, 
Scotland, UK). The tests were obtained through the same 
public notice made by Hospital de Clínicas de Porto Alegre 
(HCPA), specifically for this study, asking the manufactur-
ers to send three different lots of the same brand, whereas 
they did not know that their products would be under-
going analysis. There was no preference for any specific 
brand, except for Strip Test Plus®, as it is the standard test 
used in HCPA. All lots were within the expiry date. 
The Strip Test Plus® test lots consisted of a dipstick 
with sensitivity of 25 mIU/mL for the diagnosis of preg-
nancy. According to the manufacturer, the test has a 99.4% 
concordance with results obtained with other tests11. Test 
reading was carried out five minutes aer immersing the 
test strip in the urine sample. 
The BioEasy® test lots consisted of a dipstick 
from sensitivity of 25 mIU/mL. The manufacturer adver-
tises sensitivity and specificity of 100% (95% CI: 0.95 to 1) 
and accuracy of 100% (95% CI: 0.98 to 1) for the detection 
of β-hCG in the urine, which was evaluated with n = 15914. 
The test results were verified five minutes aer immersion 
of the test strips for twenty seconds in the urine samples. 
The Visitect Pregnancy® test lots consisted of a strip 
and a dropper for each individual test. The manufacturer 
advertises that the test sensitivity is from 10 mIU/mL, its 
specificity does not undergo cross-reaction and its accu-
racy shows good correlation when performed in parallel 
with other pregnancy tests on the market, using known 
positive and negative controls15. The test was performed by 
placing two drops of each urine sample with an individual 
dropper and the result was verified aer five minutes.
SAMPLE PREPARATION
A male urine sample was used as diluent. The recom-
binant β-hCG concentration at a concentration of 
5,000,000 IU/mL (Choragon Ferring GmbH, Kiel, Ger-
many) was diluted in 49 mL of urine, resulting in a work-
ing solution at a concentration of 100 mIU/mL. From this 
solution, serial 50, 12.5 and 6.25 mIU/mL dilutions were 
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made, in a final volume of 10 mL. In one of the test tubes, 
10 mL of pure urine was prepared for analysis as a negative 
control. During the dilutions, materials were not reused to 
prevent contamination.  
Urine and recombinant β-hCG were stored up to 72 
hours under refrigeration at 4ºC, and were not frozen. 
The test tubes at concentrations 100; 50; 25; 12.5; 6.25 and 
0 mIU/mL were codified and randomly prepared for anal-
ysis by one investigator (GSM), who did not participate in 
the test reading. 
TEST PERFORMANCE AND READING 
One of the authors (RAC), blinded to the concentrations 
in the tubes, performed the tests and carried out the read-
ings according to the manufacturers’ instructions, deter-
mining them as positive, when there were two distinct 
markings on the test; negative when the test line was ab-
sent; when the positive test line was not clear, the test was 
considered indeterminate. Tests without the control line 
were discarded. For readings, indeterminate results were 
considered positive, as they could mean positivity below 
the cutoff point recommended by the manufacturer. 
The readings were performed consecutively, without 
interruption, under the same conditions of temperature 
and pressure to prevent measurement bias. 
SAMPLE SIZE
The sampling was based on similar studies, published in 
the international literature7 and by the Food and Drug 
Administration of the United States16 and considering an 
alpha error of 0.05; a 0.99 power to detect an increase of 
81% among controls and cases. These parameters estab-
lished 10 different replicates for each concentration (n = 6) 
for each lot (n  =  3 lots), in the three analyzed brands 
(n = 10 x 6 x 3 = 180 analysis for each brand).
STATISTICAL ANALYSIS AND ETHICAL ASPECTS 
Data were analyzed using a contingency table for diagnos-
tic test evaluation parameters, using the soware GrahPad 
InStat, release 3.00 for Mac (GraphPad Soware, San Di-
ego California USA, www.graphpad.com) and the diag-
nostic test calculator (http://araw.mede.uic.edu/cgi-bin/
testcalc.pl) for a confidence interval of 95%.  
The comparison of accuracy between the three prod-
ucts and the lots was assessed using two-way ANOVA 
(product and lot), and considering significant a p < 0.05. 
For performance analysis, we considered three differ-
ent scenarios: (1) product performance with negative 
concentrations and concentrations  ≥  the cutoff recom-
mended by the manufacturer, (2) product performance 
with all concentrations, having as positive values the cut-
offs established by the manufacturer, (3) product perfor-
mance with all concentrations, but having 12.5 mIU/ mL, 
as positive value (equivalent to pregnancy), as suggested 
by Butler et al.8
Scenario 1 represents the manufacturers’ data; sce-
nario 2, the clinical practice, which considers the value of 
10 or 25 mIU/mL a pregnancy diagnosis, and scenario 3, 
an intermediate situation, where the diagnosis of preg-
nancy is suggested from 12 mIU/mL, as this is the mini-
mum concentration found in pregnancies with 4 weeks 
of gestational age8. This study was approved by the Re-
search Ethics Committee of the Research and Postgradu-
ate Group of Hospital de Clínicas de Porto Alegre, under 
# 09-301.  
RESULTS
All tests showed positive internal control and it was not 
necessary to discard any test. The three brands identified 
the minimum values specified by the manufacturers, if 
indeterminate results were considered positive. The indi-
vidual data of each lot are shown in Table 1. Some strips 
were positive for hCG even at lower concentrations than 
the threshold specified by the manufacturer (Table  1). 
Table 2 represents scenario 1, product performance using 
only the negative controls (zero) and values ≥ product 
cutoff, without intermediate values. Scenario 2 is shown 
in Table 3, which describes product performance to iden-
tify any concentration of β-hCG in the urine, having the 
cutoffs of each product as positive tests. 
Product Strip Test Plus® BioEasy® Visitect®
Lot 1 2 3 1 2 3 1 2 3
(mUI/mL) P N I P N I P N I P N I P N I P N I P N I P N I P N I
100 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0
50 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0
25 10 0 0 9 0 1 3 0 7 8 0 2 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0
12.5 0 0 10 0 10 0 0 5 5 2 6 2 7 0 3 9 0 1 10 0 0 8 0 2 10 0 0
6.25 0 10 0 0 9 1 0 10 0 4 4 2 5 2 3 10 0 0 6 1 3 5 1 4 1 5 4
0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 9 1 0 6 4
P, positive; N, negative; I, indeterminate.
Table 1 – Test performance results per lot in each concentration. Cutoff for identification: Strip Test Plus®: 25 mIU/mL, 
BioEasy®: 25 mIU/mL and Visitect®: 10 mIU/mL. Shadowed areas identify the cutoffs
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Table  4 represents scenario 3, which shows product 
performance where values ≥ 12 mIU/mL are considered 
positive. The performance of the three brands was ana-
lyzed considering the three different scenarios. Statistical 
analysis with 2-way ANOVA showed no significant differ-
ence between brands and lots (evaluated factors), with ac-
curacy as the variable to be analyzed (Tables 5 and 6).Lots, 
as well as the different types of tests, had no effect on test 
accuracy, with a cutoff value of β-hCG ≥ 6.25 mIU/mL.  
DISCUSSION
The three analyzed brands use the principle of immu-
nochromatography with antigen-antibody reaction and 
have very similar instructions. These products vaguely 
inform the consumer about test accuracy. For instance, 
Strip Test Plus® stated that it has “an agreement of 99.4% 
with the results obtained when using other tests,” but 
gives no further information. The accuracy of the tests 
is different between lots of the same test, and lower than 
that advertised by the manufacturer, as shown in Table 5. 
These differences, however, are not statistically significant 
and do not inuence test results (Table 6). BioEasy®, on 
the other hand, gives accurate information about product 
sensitivity, specificity and accuracy, but does not inform 
which hCG concentrations were analyzed. 
The accuracy found for BioEasy®, in the present study, 
is out of the 95% CI established by the manufacturer. These 
differences may be due to the β-hCG cutoff (6.26 mIU/mL) 
that was used, which represents the clinical practice sce-
nario. If we consider scenario 1, which reects the man-
ufacturers' data, where there are only β-hCG concentra-
tions ≥ the cutoff of the product and the negative control, 
Product Strip Test Plus® BioEasy® Visitect®
n 120 120 150
Sensitivity
1
(0.96-1)
1
(0.96-1)
1
(0.96-1)
Specificity 
1
(0.88-1)
1
(0.88-1)
0.7 
 (0.5-0.85)
PPV 
1
(0.96-1)
1
(0.96-1)
0.93
(0.87-0.96)
NPV 
1
(0.88-1)
1
(0.88-1)
1
(0.83-95)
Accuracy 1 1 0.94
PLR 
∞
(3.94-964)
∞
(3.94-964)
3.33
(1.91-5.52)
NLR
0
(0-0.09)
0
(0-0.09)
0
(0-0.1)
PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR,  negative likelihood ratio. Numbers between parentheses 
(95% CI).
Table 2 – Diagnostic test results for hCG in urine, using the product cutoffs for the diagnosis of hCG in urine and only the 
negative control – Scenario 1
Product Strip Test Plus® BioEasy® Visitect®
Lot 1 2 3 Total 1 2 3 Total 1 2 3 Total
n 60 60 60 180 60 60 60 180 60 60 60 180
Sensitivity
0.8
(0.66-89)
0.62
(0.47-75)
0.7
(0.55-82)
0.71
(0.62-0.77)
0.8
(0.66-0.89)
0.96
(0.86-0.99)
1
(0.92-1)
0.92
(0.86-95)
0.98
(0.89-0.99)
0.98
(0.89-0.99)
0.9
(0.78-0.96)
0.93
(0.87-0.96)
Specificity 
1
(0.69-1)
1
(0.69-1)
1
(0.69-1)
1
(0.88-1)
1
(0.69-1)
1
(0.69-1)
1
(0.69-0.1)
1
(0.88-1)
1
(0.69-1)
0.9
(0.55-0.99)
0.6
(0.26-0.87)
0.7 
 (0.5-0.85)
PPV 
 
1
(0.91-1)
1
(0.88-1)
1
(0.9-1)
1
(0.96-1)
1
(0.91-1)
1
(0.92-1)
1
(0.92-1)
1
(0.97-1)
1
(0.91-1)
0.98
(0.89-0.99)
0.92
(0.8-0.97)
0.94
(0.88-0.97)
NPV 
0.5
(0.27-0.72)
0.34
(0.17-0.54)
0.40
(0.21-0.61)
0.41
(0.29-0.52)
0.5
(0.27-0.72)
0.83
(0.51-0.97)
1
(0.69-1)
0.71
(0.55-0.84)
0.91
(0.58-0.99)
0.9
(0.55-0.99)
0.55
(0.23-0.83)
0.66
(0.46-0.81)
Accuracy 0.83 0.68 0.75 0.76 0.83 0.96 1 0.93 0.98 0.96 0.85 0.89
PLR ∞ ∞  ∞
∞
(2.76-685)
∞
 
∞
 
∞
 
∞
(3.64-889)
∞
 
2.25
 
2.22
 
3.09
(1.78-5.35)
NLR 
0.2
(0.12-0.38)
0.38
(0.28-0.58)
0.3
(0.21-0.49)
0.29
(0.23-0.38)
0.2
(0.12-0.38)
0.04
(0.02-0.17)
0
(0-0.16)
0.08
(0.05-0.14)
0.02
(0.01-0.15)
0.02
(0-0.16)
0.17
(0.06-0.44)
0.1
(0.06-0.19)
PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR,  negative likelihood ratio. Numbers between parentheses (95%CI).
Table 3 –  Diagnostic test results for hCG in urine at any concentration – Scenario 2
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two brands (Strip Test Plus® and BioEasy®) show speci-
ficity, sensitivity and accuracy of 100%, as advertised by 
the manufacturer (Table 2). The brand Visitect ® showed 
an indeterminate result for 5 negative samples, which re-
duced its specificity and its accuracy was 94% (Table 2).
Indeterminate tests (weakly positive) were seen in all 
samples and lots of the three products. None of the man-
ufacturers distinguishes the results in which the color-
ation or marks of positivity was not clear. We verified that 
the majority of indeterminate results were seen at β-hCG 
concentrations below the product threshold (Table  1). 
Consequently, we considered the test as positive. There-
fore, the results of the manufacturers are compatible with 
our findings within scenario 1; however, this does not ap-
ply to clinical practice. 
Table 3 shows scenario 2, where we used any presence 
of hCG in the urine as a positive value. In scenario 2, 
Variable Strip Test Plus® BioEasy® Visitect®
Sensitivity
 
0.88
(0.8-0.92)
0.95
(0.89-0.98)
1
(0.96-1)
Specificity 
0.98
(0.91-0.99)
0.6
(0.46-0.72)
0.53 
 (0.4-0.66)
PPV 
0.99
(0.94-0.99)
0.83
(0.75-0.88)
0.81
(0.73-0.87)
NPV 
0.8
(0.68-0.88)
0.86
(0.71-0.94)
1
(0.89-1)
Accuracy 0.91 0.83 0.84
PLR 
52.5
(7.51-367)
2.38
(1.74-3.25)
2.14
(1.63-2.79)
NLR 
0.13
(0.08-0.2)
0.08
(0.04-0.19)
0
(0-0.19)
PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio. Numbers between 
parentheses (95% CI).
Table 4 –  Diagnostic test results for hCG in urine, considering a positive result  ≥ 12.5 mIU/mL (n = 180) – Scenario 3
 Test accuracy
  Strip Test Plus® BioEasy® Visitect®
Lot 1 0.8333 0.8330 0.98
Lot 2 0.6800 0.9700 0.97
Lot 3 0.7500 1.0000 0.85
Table 5 – Accuracy raw data of each test per lot, having a 
β-hCG threshold of 6.25 mIU/mL
Summary Count Sum Mean Variance
Lot 1 3 2.6463 0.8821 0.0071
Lot 2 3 2.62 0.8733 0.0280
Lot 3 3 2.6 0.8666 0.0158
Strip Test Plus® 3 2.2633 0.7544 0.0058
BioEasy® 3 2.803 0.9343 0.0079
Visitect® 3 2.8 0.9333 0.0052
ANOVA
Source of 
variation
Sum  
of squares
Degree of 
freedom
Square 
 mean
F p-value F crit
Lots 0.0003 2 0.0001 0.0190 0.9812 6.9442
Tests 0.0643 2 0.0321 3.4112 0.1366 6.9442
Error 0.0377 4 0.0094
Table 6 – Two-way ANOVA test results with the test brands and lots (evaluated factors) and accuracy as the variable to be 
analyzed 
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the performance of each product deteriorated. The accu-
racy between the products and their lots ranged between 
68% and 100%. This scenario is what the clinician sees in 
everyday practice. The clinician considers the diagnosis 
of pregnancy is confirmed when the test result is positive 
for β-hCG levels ≥ 25 mIU/mL, and below this threshold, 
the patient is considered non-pregnant. A more detailed 
analysis can verify that when there is a positive result for 
Strip Test Plus® and BioEasy®, the clinician will be sure 
that there is β-hCG level ≥ 25 mIU/mL in 100% (95% CI: 
0.96 to 1) of the cases, confirming the pregnancy. On the 
other hand, with a negative result, this certainty decreas-
es to 41% (95% CI: 0.29 to 0.52) for the Strip Test Plus®, 
as there may be very early pregnancies, and consequently, 
with β-hCG levels < 25 mIU/mL. These observations may 
explain the discrepancies reported in the literature12,13. 
For the clinician, the question to be answered is: which 
test should be used to diagnose or rule out pregnancy? To 
answer this, Butler et al7. reported that the concentration 
of hCG in urine at 4 weeks of gestation ranges from 12 to 
2,438 IU/L, or 12 to 2,438 mIU/mL. Therefore, scenario 
3 is represented in Table 4, where values  ≥ 12.5 mIU/mL 
are considered positive, and those  6.25 mIU/mL, nega-
tive. For the clinician, the most important value of an 
auxiliary test is the likelihood ratio14. Together with these 
data, one associates the pre-test odds, i.e., the prevalence 
of cases of pregnancy in the setting where the test is per-
formed. A recent study published by our group showed 
that the prevalence of pregnant women who were treated 
at the gynecological emergency department, without a 
pregnancy diagnosis, is 18.5%17.  
Considering these data, we verify that Strip Test 
Plus®, when positive, has a probability of 92.3% that 
the urinary β-hCG is ≥ 12.5 mIU/mL, and therefore we 
conclude that the patient is pregnant; as for Visitect®, 
when it shows a negative result, the chance of having a 
β-hCG ≥ 12.5 mIU/mL is zero, therefore ruling out the 
diagnosis of pregnancy. [These values  were obtained us-
ing the formula: positive post-test probability = post-test 
odds/(post-test odds +1), where post-test odds = pre-
test odds x likelihood ratio; pretest odds = prevalence/
(1-prevalence)]15. A negative result of the Strip Test Plus® 
indicates that there is a 2.9% chance of pregnancy and 
the test did not recognize the pregnancy because the 
β-hCG concentration is approximately 12 mIU/mL in a 
4-week gestation7. 
A positive aspect of this study is the use of recombi-
nant β-hCG at concentrations known as the gold stan-
dard. This substitutes the measurements of β-hCG by 
radioimmunoassay or enzyme immunoassay. Addition-
ally, with pre-defined concentrations of β-hCG, it was 
possible to identify whether the products identified the 
lower limits of sensitivity specified by the manufacturer, 
that is, 10 mIU/mL and 25 mIU/mL.  
The negative results, at urinary concentrations of 
6.25 and 12.5 mIU/mL of β-hCG, as well as positive re-
sults in negative controls, may partly explain the situa-
tions of false positive and false negative results in clinical 
practice16. Another explanation, in addition to the limits 
below the cutoff established by the product manufac-
turer, is the possibility that the monoclonal antibody 
against the regular hCG that is found in the kit does not 
react against hyperglycosilated hCG (H-hCG), which 
comprehends 61% of all immunoreactive hCGs in the 
first four weeks of gestation7.  
CONCLUSION
In conclusion, all three products analyzed recognize 
β-hCG in the urine at sensitivity cutoffs announced by 
manufacturers, if the indeterminate cases are consid-
ered positive. Some lots of three brands identified val-
ues below the cutoff advertised in the product package 
insert. Strip Test Plus® has the best accuracy in iden-
tifying urinary concentrations of β-hCG, with a posi-
tive likelihood ratio of 52.5, while Visitect® has the best 
performance to rule out a pregnancy, with a negative 
likelihood ratio of 0.   
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